Category News

EAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. today presented new and significant data demonstrating the superiority…

Read MoreEAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study

Roche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients

Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of its benefit-risk profile in non-ambulatory patients with Duchenne muscular dystrophy…

Read MoreRoche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients
Multiple Myeloma

TALVEY + TECVAYLI Provide Durable Responses in Extramedullary Multiple Myeloma

Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs) and…

Read MoreTALVEY + TECVAYLI Provide Durable Responses in Extramedullary Multiple Myeloma

Astellas, Mitsubishi Research Institute Team Up to Support Japanese Pharma Startups

Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced a significant new collaboration aimed at strengthening Japan’s role as…

Read MoreAstellas, Mitsubishi Research Institute Team Up to Support Japanese Pharma Startups

FDA Approves KEYTRUDA for Neoadjuvant and Adjuvant Treatment of PD-L1+ Resectable Head & Neck Cancer

FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®…

Read MoreFDA Approves KEYTRUDA for Neoadjuvant and Adjuvant Treatment of PD-L1+ Resectable Head & Neck Cancer

J&J’s Dual-Target CAR T-Cell Therapy Shows Promise in Large B-Cell Lymphoma

Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Clinical Results in Large B-Cell Lymphoma Johnson & Johnson recently presented promising first-in-human data from its ongoing Phase 1b study evaluating JNJ-90014496 (JNJ-4496) — an investigational, dual-targeting, autologous chimeric antigen…

Read MoreJ&J’s Dual-Target CAR T-Cell Therapy Shows Promise in Large B-Cell Lymphoma